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Abstract 
Background 
Only few studies have modelled smoking histories by combining smoking intensity and 
duration to show what profile of smoking behaviour is associated with highest risk of bladder 
cancer. This study aims to provide insight into the association between smoking exposure 
history and bladder cancer risk by modelling both smoking intensity and duration in a pooled 
analysis. 
Methods 
Data from 15 case-control studies included in the BLadder cancer Epidemiology and 
Nutritional Determinants (BLEND) study were used, including a total of 6,874 cases and 
17,727 controls. To jointly interpret the effects of intensity and duration of smoking, excess 
odds ratios (EOR) per pack-year were modelled by intensity continuously to estimate the risk 
difference between smokers with long duration/low intensity and short duration/high 
intensity.  
Results 
The pooled EOR model indicated that for a fixed number of pack-years, smoking for a 
longer duration at lower intensity was more deleterious for bladder cancer risk than smoking 
more cigarettes/day for a shorter duration. Similar patterns were observed within individual 
study samples. 
Conclusions 
This pooled analysis shows that long duration/low intensity smoking increases 
bladder cancer risk more than short duration/ high intensity smoking within equal pack-year 
categories, thus confirming studies in other smoking-related cancers and demonstrating that 
reducing exposure history to a single metric such as pack-years is too restrictive.  
Keywords: bladder cancer, smoking history, pooled analysis  
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Introduction 
Smoking is a significant modifiable risk factor for urothelial bladder cancer (UBC) and 
studies demonstrate a differential dose-response pattern for intensity and duration(1). Many 
studies have investigated smoking behaviour in relation to UBC, showing separate risk 
estimates for intensity, duration and pack-year; but only a few studies have modelled 
complex smoking histories including all aspects of exposure such as duration, intensity and 
time since smoking cessation(2,3). 
 Most studies establishing the association between smoking history and various 
diseases use cumulative exposure (i.e. pack-years) in an attempt to go beyond smoking status 
only(4). However, more recently, consensus has been reached that modelling pack-years 
alone is not sufficient to identify possible mechanisms underlying such associations(5). 
Several researchers have discussed whether pack-years should be used to measure effects of 
smoking or whether pack-years can be useful in making biologically credible models that 
provide unbiased information on complex smoking exposure histories(5,6), and 
circumventing multicollinearity issues(7). Although, simultaneous and interpretable 
modelling of the effects of smoking behaviour has been a research topic for several decades 
for other diseases, this have been infrequently investigated in UBC research(8,9). 
 Two case-control studies in UBC both suggested that among equal pack-year 
categories, individuals who had smoked relatively fewer cigarettes per day for longer 
duration were at a higher risk of UBC compared to those who smoked more cigarettes per 
day over a shorter duration(2,3). In these studies, estimates of the excess odds ratio (EOR) 
per pack-year were compared across categories of smoking intensity. Recently, similar 
models have been further developed and tested to also include time since smoking 
cessation(10) or stratification by age category to consider timing of exposure (11). Using an 
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alternative approach, two other case-control studies data also showed that duration is the 
over-riding factor in determining the risk of bladder cancer(12,13). 
 The aim of this study was to investigate the association between cumulative smoking 
exposure and UBC risk and to model and interpret the various smoking effects, in a uniquely 
large pooled sample of case-control studies. 
6 
 
Methods 
Study data 
The BLadder cancer Epidemiology and Nutritional Determinants (BLEND) consortium 
currently consists of 19 case-control studies and 14 cohort studies investigating the 
association between lifestyle behaviours and UBC risk. For this analysis, we included 15 
case-control studies providing complete data on smoking behaviour, including; smoking 
status, intensity and duration, These included 6,824 cases and 17,727 controls originating 
from Italy(13–15), Germany(16,17), Belgium(18), Sweden(19), Canada(20), the USA(21–26) 
and China(27). All smoking data were either collected through interview-administered 
questionnaires (n=6) or self-administered questionnaires (n=9). Further details on the 
methodology of this consortium have been described(28). 
 
Statistical analysis and delivery rate of exposure 
  A statistical approach described by Vlaanderen et al. was utilised(10). The pooled 
smoking data were divided into quintile categories of pack-years, years of smoking, 
cigarettes per day and time since smoking cessation (TSC). Odds ratios (ORs) for these 
categories were obtained using a multilevel random effect logistic regression model adjusting 
for study, age and sex as covariates. Subsequently, total pack-years were cross-classified by 
cigarettes smoked per day and years of smoking to estimate the ORs in combined exposure 
categories with never smokers as the reference group. Finally, we fitted an exponential model 
to estimate the EOR per pack-year by smoking intensity to investigate the independent effect 
of cigarette smoking duration and intensity of cigarette smoking on UBC risk. In other words, 
with these models, long duration/low intensity smokers are compared to short duration/high 
intensity smokers with equal pack-years. 
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We used the model: 
OR (d) = 1 + ßd x exp(g1(n)) 
where the model was fitted using continuous pack-years (d), continuous intensity (n) and g1 
as a 3-knot restricted cubic spline function of continuous smoking intensity (knots located at 
20
th
, 50
th
 and 80
th
 percentile of the distribution of intensity of all smokers). This model was 
applied to each of the 15 studies. 
The results from such models describe delivery rate patterns of exposure to tobacco 
smoking in relation to UBC risk. The delivery rate is described through estimating how 
increasing intensity or duration within a fixed number of pack-years influences UBC risk. For 
example, an inverse exposure rate effect for intensity would mean that the EOR/pack-year 
(the strength of association) decreases with more cigarettes smoked per day (and thus 
decrease duration) or alternatively the OER/pack-year increases with fewer cigarettes per day 
(and increased duration). Consequently, for two individuals with equal total pack-years, 
greater risk accrues to the individual smoking for longer duration at lower intensity. 
A sensitivity analysis was performed with data from 5 studies that provided detailed 
data on TSC by adding an extra 3-knot restricted cubic spline (knots at the 20
th
, 50
th
 and 80
th
 
percentiles of the distribution of TSC of all former smokers) to the model, since incorporating 
TSC into these models might provide a better fit with the data(10). Additionally, different 
knot locations (at the 10
th
, 50
th
 and 90
th
 and 5
th
, 50
th
 and 95
th
 percentiles) were applied to 
assess the robustness of the associations. The fit of the models with different knot locations 
were tested using the Akaike information criterion (AIC). 95% confidence intervals (CIs) for 
the EOR models were estimated through bootstrapping via 1,000 replications of the original 
data. The 2.5
th
 and the 97.5
th
 percentile of the subsequent distribution are shown in the fitted 
model. To assess the level of heterogeneity underlying this EOR model, it was also repeated 
in individual BLEND study populations.  
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Results 
Smoking characteristics in included studies 
Table 1 shows baseline characteristics for all included case-control studies. In most 
studies, at least 80% of current smokers at baseline smoked more than 10 cigarettes a day. 
The only study in which this proportion was much lower than the mean proportion for both 
current smokers (14%) and former smokers (4%) was the Swedish study, with 14% and 4% 
respectively(19) (Table 1). Nine of the 15 studies demonstrated that 90% of current smokers 
had smoked for at least 20 years. This percentage was lower among former smokers (between 
70% and 80%) (Table 1). One study from the USA(22) provided details on smoking 
behaviour among current smokers only. 
 
INSERT TABLE 1 HERE 
 
Risk estimates for smoking behaviour  
Based on the pooled results, current smokers had a higher UBC risk than never 
smokers (OR=2.23, 95% CI=2.05-2.42) (Table 2). Tests for linear trend showed increasing 
risks across quintile categories of intensity, duration and pack-years (p-values<0.001). 
Furthermore, smoking cessation was related to a lower UBC risk compared to current 
smokers (Table 2), with an OR of 0.40 (95% CI=0.32-0.51) for those who had quit smoking 
more than 30 years before UBC diagnosis. UBC risk for those who had quit smoking 30 
years prior to diagnosis was very similar compared to those who had never smoked 
(OR=1.04, 95% CI=0.81-1.32). 
 
INSERT TABLE 2 HERE 
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Delivery rate patterns of exposure to smoking in relation to UBC risk 
Fifteen ORs, with never smokers as reference category, were calculated in the analysis 
stratified by intensity quintile (Figure 1), whilst 20 ORs were estimated in the analysis 
stratified by duration quintile (Supplemental Figure 1) because data were sparse in the 
intensity categories. None of the associations showed any departures from linearity (p>0.05 
for all categories), which means that the EOR model as it is presented is valid in meeting the 
assumption about linearity of association between exposure and disease. 
 
INSERT FIGURE 1 HERE 
 
The EOR per pack-year and 95% CI by continuous smoking intensity (cigarettes/day) 
resulting from the cubic spline model are plotted in Figure 2. Additionally, the slope resulting 
from the model including splines for TSC is also shown. The model excluding TSC had a 
slightly better fit to the data (AIC=23,140) compared to the model including TSC 
(AIC=24,219), probably because the effect of TSC was heterogeneous between the few 
included studies. Both curves show an inverse delivery rate pattern, whereby with increasing 
cigarettes smoked per day (and decreasing duration) the EOR per pack-year decreases. This 
indicates that for equal pack-years, smoking for a longer duration (at few cigarettes/day) is 
more strongly associated with UBC risk than smoking more cigarettes per day (for a shorter 
duration). As can be observed from the bootstrapped 95% CI, the plotted curve had the 
highest number of participants for individuals smoking between 10 and 40 cigarettes per day 
which included 79% of all smokers in this consortium, and therefore the shape of the curve is 
most reliable on this interval. 
 
INSERT FIGURE 2 HERE 
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Heterogeneity was small among the 10 individual studies in which EOR models could 
be fit with the original spline settings (Supplemental Figure 2A). For three studies(14,23,25) 
the model did not fit because of their data distribution (e.g. 19 cigarettes per day represented 
the 44
th
 percentile and 20 cigarettes per day represented the 82th percentile of the data), and 
there was limited power within 2 studies(16,27) (too many levels of intensity with no cases). 
When moving the splines to positions fitting the data distribution in the three studies with a 
different data distribution, the three added curves show a similar shape to the EOR curves 
from the 10 studies that were estimated with the original spline settings (Supplemental Figure 
3). Additionally, the EOR models within the 3 studies that included sufficient data on 
TSC(15,18,20) were also similar (Supplemental Figure 2B).  
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Discussion 
We have provided insight into the complex exposure patterns of lifetime smoking behaviour 
and the impact on UBC risk. We have shown an inverse delivery rate pattern indicating that, 
for equal pack-years of smoking, less cigarettes per day over a longer duration is more 
deleterious for UBC risk than smoking more cigarettes per day over a shorter duration. The 
results of this pooled analysis of 15 case-control studies are in line with data from two other 
previous case-control studies on UBC applying a similar approach (2,3).  
 
Robustness of results 
 We applied the model as described by Vlaanderen et al, but a similar approach was 
first described in a lung cancer study(29), known as the L-C (Lubin-Caparaso) model, which 
has also been applied in a pooled analysis of case-control studies on head and neck 
cancer(30) and in two individual UBC case-control studies(2,3). Alongside these models, 
Brennan et al described a different approach in 2000 which is based on stratification of both 
duration and intensity and estimating ORs in all strata. They also observed that duration was 
more important in predicting UBC risk than intensity(12). Nevertheless, the approach 
Brennan et al. took does not allow for an unambiguous interpretation of the separate RRs; the 
question remains whether the increase in risk derives from duration or from pack-years, 
which increases concurrently. The modelling approach applied in our study does answer this 
question since the results show the risk difference between long duration/low intensity and 
short duration/high intensity smokers with equal pack-years.  
Similar ORs were observed for both women and men, although more men smoked at 
least 10 cigarettes per day (86%) compared to women (73%), possibly explaining differences 
in precision of risk estimates, in addition to the smaller sample of women in the included 
studies. Furthermore, observed ORs for smokers might be underestimated since the pooled 
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OR for current smokers was markedly lower than observed in a large meta-analysis(1) 
(OR=2.23 in the current sample vs OR=3.14 in the meta-analysis). This might be explained 
by some misclassification of smoking information collected through self-administered 
questionnaires in the 15 included studies or differences in data collection in the meta-
analysis.  
Notwithstanding, the selection of 15 studies that agreed to participate in this 
consortium might also not be representative of all bladder cancer case-control studies present, 
since most participating studies are from either Europe and the USA. 
Little heterogeneity in the range of predicted EORs per pack-year by cigarettes per 
day between the included studies was observed (Supplemental Figure 2). However, some 
heterogeneity in magnitude of estimated EORs per pack-year remains between the studies, 
which may be explained by several factors such as geographical location(1) and calendar year 
in which cases and controls were recruited(31). Since only 5 studies provided sufficient data 
on TSC, this pooled analysis might not have had sufficient power to include TSC as an extra 
spline. 
 
Strengths and limitations of the EOR model and interpretation of results 
Although the EOR model can provide a more detailed insight into the association 
between smoking behaviour and disease risk, there are some other factors not in this model 
that also need to be considered. Since a more vigorous inhalation pattern has been shown to 
be associated with a higher UBC risk(32,33), the observed inverse delivery rate pattern might 
reflect differences in inhalation patterns among cigarette smokers. It is generally believed that 
light smokers inhale more vigorously compared to heavier smokers to achieve the same 
amount of nicotine consumption(34,35), therefore possibly confounding the risk estimates 
comparing heavy to light smokers. However, inhalation was not found to be a confounder of 
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pack-years-adjusted cigarettes per day patterns in a lung cancer study(29). Data on inhalation 
patterns was not available for the study participants within BLEND. 
Moreover, since no data were available on time periods during which study 
participants might have smoked less (or more) than their average estimated intensity we 
could not account for this.  
Due to the retrospective nature of data collection in case-control studies including 
such detailed data on smoking behaviour would not have been possible in this pooled 
analysis; however, in prospective studies such periodical changes in smoking intensity could 
be accounted for when applying the EOR models by adding TSC or time since moderation 
splines if data is gathered. Nevertheless, the 5 case-control studies that did gather data on 
TSC showed a similar shape of the EOR curve (Figure 2). This EOR model provides one of 
the most detailed UBC risk predictions following different durations and intensities of 
smoking. Nevertheless, there have been other methods to model smoking history in relation 
to cancer such as the comprehensive smoking index which also incorporates intensity, 
duration and time since cessation(36). 
 
Smoking behaviour and molecular pathways to bladder carcinogenesis 
Tobacco smoke contains many carcinogens that can contribute to carcinogenesis in 
the bladder. These carcinogens can form DNA adducts and, when multiple types of DNA 
adducts are combined, they contribute greatly to human cancer risk(37). Several studies have 
shown that nicotine-derived nitrosamine ketones (NNK), methyl and other DNA adducts are 
more frequently present in UBC patients who have smoked compared to those who have 
never smoked(38,39). Nevertheless, it is not clear how NT2 status is involved in an inverse 
smoking intensity effect in at population level. It has not been measured whether rapid 
acetylators are more likely to be high intensity/short duration smokers. Moreover, there is 
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heterogeneity in the efficiency of DNA repair pathways between individuals; for example, 
those who have a slow N-acetyltransferase phenotype have a higher risk of UBC when they 
smoke(40), and DNA repair processes can also be negatively influenced by longer smoking 
duration or higher cumulative exposure (in pack-years) (41). This indicates that the DNA 
adduct pathway of UBC pathogenesis is important in smoking-related UBC. Although not 
directly implied from our data as we did not measure DNA adducts, the risk difference 
between long duration/low intensity smokers and short duration/high intensity smokers could 
be explained by the longer exposure period for accumulation of smoking-related DNA 
adducts in long duration/low intensity smokers. The results from our study, as well as of 
other studies in UBC(2,3), lung cancer(10,29), and head and neck cancer(30), are consistent 
in showing that smoking fewer cigarettes over a longer duration increases disease risk more 
than smoking at a higher intensity for a shorter duration when pack-years are equal. 
Therefore, future studies should investigate differences in DNA repair pathways between 
long duration/low intensity versus short duration/high intensity smokers as the studies 
discussed in this paragraph focus only on intensity or duration separately in relation to DNA 
adducts. Nevertheless, these results have major implications for prevention at public health 
level and can impact the public’s perception on smoking and health risks.   
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Conclusion 
 
We have demonstrated that long duration/low intensity smoking behaviour is most 
strongly associated with UBC risk within equal pack-year categories in this pooled analysis, 
thereby confirming studies in two case-control studies on UBC as well as other smoking-
related cancers. Furthermore, with this model we found that reducing complex exposure 
history to a single metric such as pack-years is too restrictive, and future research should 
focus on interpretable ways to model complex cumulative exposures such as lifetime 
smoking behaviour. 
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Legends Tables & Figures 
 
Table 1.  Number of bladder cases and controls by smoking status included 
in the BLEND consortium study. 
 
Table 2. Odds ratios (OR) and 95% confidence intervals (95% CI) for 
bladder cancer according to smoking status, quintile categories for pack-
years, duration and intensity, and time since smoking cessation overall and 
by sex. 
 
Figure 1. Odds ratios (OR) for bladder cancer by cross-classified categories 
of pack-years and quintile categories of number of cigarettes smoked per 
day (CPD). Lines indicate fitted linear odds ratio models in pack-years, 
bars indicate 95% confidence intervals. Pooled data was limited to never 
and current smokers. 
 
Figure 2. Estimated excess odds ratio (EOR) per pack-year for bladder 
cancer by cigarettes per day with bootstrapped 95% confidence intervals. 
The dotted line indicates a model including an extra spline for time since 
smoking cessation. Triangles depict locations of the knots of the restricted 
cubic splines (20
th
, 50
th
 and 80
th
 percentile). 
 
Supplemental Figure 1. Odds ratios (OR) for bladder cancer by cross-
classified categories of pack-years and quintile categories of years of 
smoking. Lines indicate fitted linear odds ratio models in pack-years, bars 
indicate 95% confidence intervals. Pooled data was limited to never and 
current smokers. 
 
Supplemental Figure 2. Excess odds ratio (EOR) per pack-year by smoking 
intensity (cigarettes/day) stratified by study. Model without time since 
smoking cessation spline (panel A) and model with time since smoking 
cessation spline (panel B). Study numbers refer to reference number within 
this paper (see Table 1). 
 
Supplemental Figure 3. Excess odds ratio (EOR) per pack-year by smoking 
intensity stratified by study, including curves for three studies (116, 125, 
132) that had to be fit with alternative spline locations. Study numbers 
refer to reference number within this paper (see Table 1). 
 
 
